{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T13:58:45Z","timestamp":1781963925591,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Syst Biol Appl"],"DOI":"10.1038\/s41540-025-00613-y","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T16:34:59Z","timestamp":1771086899000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimal control theory as a method for designing multidrug adaptive therapy regimens"],"prefix":"10.1038","volume":"12","author":[{"given":"Afton","family":"Widdershins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Hohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"613_CR1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan, N., Baselga, J. & Hyman, D. M. A view on drug resistance in cancer. Nature 575, 299\u2013309 (2019).","journal-title":"Nature"},{"key":"613_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 15, 81\u201394 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"613_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0818-2","volume":"12","author":"Z-F Lim","year":"2019","unstructured":"Lim, Z.-F. & Ma, P. C. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J. Hematol. Oncol. 12, 1\u201318 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"613_CR4","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","volume":"37","author":"A Marusyk","year":"2020","unstructured":"Marusyk, A., Janiszewska, M. & Polyak, K. Intratumor heterogeneity: the rosetta stone of therapy resistance. Cancer Cell 37, 471\u2013484 (2020).","journal-title":"Cancer Cell"},{"key":"613_CR5","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168, 613\u2013628 (2017).","journal-title":"Cell"},{"key":"613_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1126\/science.959840","volume":"194","author":"PC Nowell","year":"1976","unstructured":"Nowell, P. C. The Clonal Evolution of Tumor Cell Populations: acquired genetic lability permits stepwise selection of variant sublines and underlies tumor progression. Science 194, 23\u201328 (1976).","journal-title":"Science"},{"key":"613_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.semcancer.2016.11.006","volume":"42","author":"D Wu","year":"2017","unstructured":"Wu, D. et al. Roles of tumor heterogeneity in the development of drug resistance: a call for precision therapy. Semin. Cancer Biol. 42, 13\u201319 (2017).","journal-title":"Semin. Cancer Biol."},{"key":"613_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/srep36198","volume":"6","author":"D Sun","year":"2016","unstructured":"Sun, D., Dalin, S., Hemann, M. T., Lauffenburger, D. A. & Zhao, B. Differential selective pressure alters rate of drug resistance acquisition in heterogeneous tumor populations. Sci. Rep. 6, 36198 (2016).","journal-title":"Sci. Rep."},{"key":"613_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1001\/jamaoncol.2018.3395","volume":"5","author":"K Sta\u0148kov\u00e1","year":"2019","unstructured":"Sta\u0148kov\u00e1, K., Brown, J. S., Dalton, W. S. & Gatenby, R. A. Optimizing cancer treatment using game theory: a review. JAMA Oncol. 5, 96\u2013103 (2019).","journal-title":"JAMA Oncol."},{"key":"613_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.drup.2012.10.003","volume":"15","author":"JR Pritchard","year":"2012","unstructured":"Pritchard, J. R., Lauffenburger, D. A. & Hemann, M. T. Understanding resistance to combination chemotherapy. Drug Resist. Updates 15, 249\u2013257 (2012).","journal-title":"Drug Resist. Updates"},{"key":"613_CR11","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-08-3658","volume":"69","author":"RA Gatenby","year":"2009","unstructured":"Gatenby, R. A., Silva, A. S., Gillies, R. J. & Frieden, B. R. Adaptive therapy. Cancer Res. 69, 4894\u20134903 (2009).","journal-title":"Cancer Res."},{"key":"613_CR12","first-page":"510\u2013525.e6","volume":"15","author":"MAR Strobl","year":"2024","unstructured":"Strobl, M. A. R. et al. To modulate or to skip: De-escalating PARP inhibitor maintenance therapy in ovarian cancer using adaptive therapy. Cell Syst. 15, 510\u2013525.e6 (2024).","journal-title":"Cell Syst."},{"key":"613_CR13","doi-asserted-by":"publisher","unstructured":"Hockings, H. et al. Adaptive therapy achieves long-term control of chemotherapy resistance in high grade ovarian cancer. https:\/\/doi.org\/10.1101\/2023.07.21.549688 (2023).","DOI":"10.1101\/2023.07.21.549688"},{"key":"613_CR14","doi-asserted-by":"publisher","first-page":"e84263","DOI":"10.7554\/eLife.84263","volume":"12","author":"J West","year":"2023","unstructured":"West, J. et al. A survey of open questions in adaptive therapy: bridging mathematics and clinical translation. eLife 12, e84263 (2023).","journal-title":"eLife"},{"key":"613_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40819-022-01425-y","volume":"8","author":"S Zouhri","year":"2022","unstructured":"Zouhri, S., El Baroudi, M. & Saadi, S. Optimal control with isoperimetric constraint for chemotherapy of tumors. Int. J. Appl. Comput. Math. 8, 215 (2022).","journal-title":"Int. J. Appl. Comput. Math."},{"key":"613_CR16","doi-asserted-by":"crossref","unstructured":"Zouhri, S. & EL Baroudi, M. Free end-time optimal control problem for cancer chemotherapy. Differ. Equ. Dyn. Syst. 33, 831\u2013847 (2023).","DOI":"10.1007\/s12591-023-00654-x"},{"key":"613_CR17","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1137\/S0036139998338509","volume":"60","author":"JC Panetta","year":"2000","unstructured":"Panetta, J. C. & Fister, K. R. Optimal control applied to cell-cycle-specific cancer chemotherapy. SIAM J. Appl. Math. 60, 1059\u20131072 (2000).","journal-title":"SIAM J. Appl. Math."},{"key":"613_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s40819-020-00838-x","volume":"6","author":"S Sabir","year":"2020","unstructured":"Sabir, S., Raissi, N. & Serhani, M. Chemotherapy and Immunotherapy for tumors: a study of quadratic optimal control. Int. J. Appl. Comput. Math. 6, 81 (2020).","journal-title":"Int. J. Appl. Comput. Math."},{"key":"613_CR19","first-page":"21","volume":"23","author":"SI Oke","year":"2018","unstructured":"Oke, S. I., Matadi, M. B. & Xulu, S. S. Optimal control analysis of a mathematical model for breast cancer. Math. Comput. Appl. 23, 21 (2018).","journal-title":"Math. Comput. Appl."},{"key":"613_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jtbi.2019.03.006","volume":"470","author":"JA Sharp","year":"2019","unstructured":"Sharp, J. A., Browning, A. P., Mapder, T., Burrage, K. & Simpson, M. J. Optimal control of acute myeloid leukaemia. J. Theor. Biol. 470, 30\u201342 (2019).","journal-title":"J. Theor. Biol."},{"key":"613_CR21","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.3934\/mbe.2022214","volume":"19","author":"G Haddad","year":"2022","unstructured":"Haddad, G. et al. Optimal control model of tumor treatment in the context of cancer stem cell. Math. Biosci. Eng. 19, 4627\u20134642 (2022).","journal-title":"Math. Biosci. Eng."},{"key":"613_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jtbi.2016.11.009","volume":"413","author":"C Carr\u00e8re","year":"2017","unstructured":"Carr\u00e8re, C. Optimization of an in vitro chemotherapy to avoid resistant tumours. J. Theor. Biol. 413, 24\u201333 (2017).","journal-title":"J. Theor. Biol."},{"key":"613_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jtbi.2018.09.022","volume":"459","author":"JJ Cunningham","year":"2018","unstructured":"Cunningham, J. J., Brown, J. S., Gatenby, R. A. & Sta\u0148kov\u00e1, K. Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer. J. Theor. Biol. 459, 67\u201378 (2018).","journal-title":"J. Theor. Biol."},{"key":"613_CR24","doi-asserted-by":"publisher","first-page":"e0243386","DOI":"10.1371\/journal.pone.0243386","volume":"15","author":"J Cunningham","year":"2020","unstructured":"Cunningham, J. et al. Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer. PLoS ONE 15, e0243386 (2020).","journal-title":"PLoS ONE"},{"key":"613_CR25","doi-asserted-by":"crossref","unstructured":"Gluzman, M., Scott, J. G. & Vladimirsky, A. Optimizing adaptive cancer therapy: dynamic programming and evolutionary game theory. Proc. R. Soc. B 287, 20192454 (2020).","DOI":"10.1098\/rspb.2019.2454"},{"key":"613_CR26","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.3390\/math11194025","volume":"11","author":"W Luo","year":"2023","unstructured":"Luo, W., Tan, X., Zou, X. & Tan, Q. Optimal treatment of prostate cancer based on state constraint. Mathematics 11, 4025 (2023).","journal-title":"Mathematics"},{"key":"613_CR27","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3390\/axioms12100916","volume":"12","author":"W Luo","year":"2023","unstructured":"Luo, W., Tan, X. & Shen, J. Optimal treatment strategy for cancer based on mathematical modeling and impulse control theory. Axioms 12, 916 (2023).","journal-title":"Axioms"},{"key":"613_CR28","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.apm.2022.10.016","volume":"114","author":"M Bodzioch","year":"2023","unstructured":"Bodzioch, M., Bajger, P. & Fory\u015b, U. Competition between populations: preventing domination of resistant population using optimal control. Appl. Math. Model. 114, 671\u2013693 (2023).","journal-title":"Appl. Math. Model."},{"key":"613_CR29","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1158\/1078-0432.CCR-19-0006","volume":"25","author":"JB West","year":"2019","unstructured":"West, J. B. et al. Multidrug cancer therapy in metastatic castrate-resistant prostate cancer: an evolution-based strategy. Clin. Cancer Res. 25, 4413\u20134421 (2019).","journal-title":"Clin. Cancer Res."},{"key":"613_CR30","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-19-2669","volume":"80","author":"J West","year":"2020","unstructured":"West, J. et al. Towards multidrug adaptive therapy. Cancer Res. 80, 1578\u20131589 (2020).","journal-title":"Cancer Res."},{"key":"613_CR31","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.3390\/cancers14112699","volume":"14","author":"DS Thomas","year":"2022","unstructured":"Thomas, D. S., Cisneros, L. H., Anderson, A. R. A. & Maley, C. C. In silico investigations of multi-drug adaptive therapy protocols. Cancers 14, 2699 (2022).","journal-title":"Cancers"},{"key":"613_CR32","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz, L. H. et al. RECIST 1.1\u2014standardisation and disease-specific adaptations: perspectives from the RECIST Working Group. Eur. J. Cancer 62, 138\u2013145 (2016).","journal-title":"Eur. J. Cancer"},{"key":"613_CR33","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s41559-021-01428-w","volume":"5","author":"Y Viossat","year":"2021","unstructured":"Viossat, Y. & Noble, R. A theoretical analysis of tumour containment. Nat. Ecol. Evol. 5, 826\u2013835 (2021).","journal-title":"Nat. Ecol. Evol."},{"key":"613_CR34","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0025-5564(92)90038-X","volume":"110","author":"RB Martin","year":"1992","unstructured":"Martin, R. B., Fisher, M. E., Minchin, R. F. & Teo, K. L. Optimal control of tumor size used to maximize survival time when cells are resistant to chemotherapy. Math. Biosci. 110, 201\u2013219 (1992).","journal-title":"Math. Biosci."},{"key":"613_CR35","doi-asserted-by":"publisher","first-page":"e2001110","DOI":"10.1371\/journal.pbio.2001110","volume":"15","author":"E Hansen","year":"2017","unstructured":"Hansen, E., Woods, R. J. & Read, A. F. How to use a chemotherapeutic agent when resistance to it threatens the patient. PLOS Biol. 15, e2001110 (2017).","journal-title":"PLOS Biol."},{"key":"613_CR36","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3934\/mbe.2013.10.803","volume":"10","author":"U Ledzewicz","year":"2013","unstructured":"Ledzewicz, U. et al. On the MTD paradigm and optimal control for multi-drug cancer chemotherapy. Math. Biosci. Eng. 10, 803\u2013819 (2013).","journal-title":"Math. Biosci. Eng."},{"key":"613_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-016-2164-x","volume":"16","author":"H Murphy","year":"2016","unstructured":"Murphy, H., Jaafari, H. & Dobrovolny, H. M. Differences in predictions of ODE models of tumor growth: a cautionary example. BMC Cancer 16, 1\u201310 (2016).","journal-title":"BMC Cancer"},{"key":"613_CR38","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3934\/mbe.2004.1.223","volume":"1","author":"BM Adams","year":"2004","unstructured":"Adams, B. M. et al. Dynamic multidrug therapies for HIV: optimal and STI control approaches. Math. Biosci. Eng. 1, 223\u2013241 (2004).","journal-title":"Math. Biosci. Eng."},{"key":"613_CR39","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3934\/mbe.2012.9.899","volume":"9","author":"D Thakur","year":"2012","unstructured":"Thakur, D., Marchand, B., Thakur, D. & Marchand, B. Hybrid optimal control for HIV multi-drug therapies: a finite set control transcription approach. Math. Biosci. Eng. 9, 899\u2013914 (2012).","journal-title":"Math. Biosci. Eng."},{"key":"613_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s43856-022-00110-x","volume":"2","author":"MAR Strobl","year":"2022","unstructured":"Strobl, M. A. R. et al. Spatial structure impacts adaptive therapy by shaping intra-tumoral competition. Commun. Med. 2, 1\u201318 (2022).","journal-title":"Commun. Med."},{"key":"613_CR41","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1158\/0008-5472.CAN-17-2649","volume":"78","author":"JA Gallaher","year":"2018","unstructured":"Gallaher, J. A., Enriquez-Navas, P. M., Luddy, K. A., Gatenby, R. A. & Anderson, A. R. Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies. Cancer Res. 78, 2127\u20132139 (2018).","journal-title":"Cancer Res."}],"container-title":["npj Systems Biology and Applications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41540-025-00613-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-025-00613-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-025-00613-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T16:00:53Z","timestamp":1771344053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41540-025-00613-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["613"],"URL":"https:\/\/doi.org\/10.1038\/s41540-025-00613-y","relation":{},"ISSN":["2056-7189"],"issn-type":[{"value":"2056-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"28 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}